Krystal Biotech, Inc. $KRYS Shares Purchased by Woodline Partners LP

Woodline Partners LP boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 0.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 222,043 shares of the company’s stock after acquiring an additional 941 shares during the quarter. Woodline Partners LP’s holdings in Krystal Biotech were worth $40,034,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Brooklyn Investment Group grew its stake in Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after acquiring an additional 105 shares during the period. Twin Tree Management LP acquired a new stake in Krystal Biotech during the 1st quarter worth $29,000. Fifth Third Bancorp boosted its stake in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after purchasing an additional 105 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock worth $58,000 after purchasing an additional 177 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Krystal Biotech during the 1st quarter worth $74,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

KRYS has been the topic of several recent research reports. Bank of America lowered their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. Chardan Capital lowered their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a “buy” rating on the stock in a research note on Friday, August 22nd. Citigroup reaffirmed a “neutral” rating and set a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Friday, August 22nd. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $210.38.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares in the company, valued at $216,924,382.80. The trade was a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is owned by insiders.

Krystal Biotech Stock Down 2.7%

NASDAQ KRYS opened at $141.21 on Wednesday. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $207.84. The business’s fifty day simple moving average is $146.85 and its 200-day simple moving average is $153.41. The firm has a market cap of $4.09 billion, a PE ratio of 28.70 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).